Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101170 | 0.84 | HTT (0.32) | — | |
| SCHEMBL11219359 | 0.83 | CHRM5 (0.37) | CA2CA12CA1CA9CHKA | |
| SCHEMBL27672361 | 0.81 | SIGMAR1 (0.40) | — | |
| SCHEMBL5874892 | 0.81 | CHRM5 (0.38) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5874356 | 0.81 | CA2 (0.34) | CA2CA12CA1CA9CHKA | |
| SCHEMBL27576738 | 0.79 | HTT (0.30) | — | |
| SCHEMBL2786080 | 0.79 | HTT (0.30) | — | |
| SCHEMBL27553618 | 0.79 | HTT (0.30) | — | |
| SCHEMBL27173938 | 0.78 | CHRM5 (0.36) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5875053 | 0.77 | CHRM5 (0.30) | CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501242-B2 | Methods and compositions for treating neoplasia | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-08-06 | — | — | US | claimed |
| US-20120156212-A1 | METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION | 2012-06-21 | — | — | US | claimed |
| WO-2010138955-A2 | METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-12-02 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10583086-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-10231938-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180071219-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180028449-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2018-02-01 | — | — | US | disclosed |
| US-9682043-B2 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| CN-106860417-A | The compound sustained-released tablet and production technology of a kind of new heart failure resistance disease | 上药东英（江苏）药业有限公司 | 2017-06-20 | — | — | CN | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1021204-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5894029-A | Method of making pet snack food | PUREBRED PET PRODUCTS, INC. (US) | 1999-04-13 | — | — | US | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156212-A1 | METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA | TYMS, UNG, TYMP | CA2 1772/4885CA12 1856/4885CA1 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.